"I am deeply honored to have been selected to help launch this important new special section of the Journal of Translational Medicine," Mr. Silva said. "Today, most regenerative medicine research remains confined to the bench rather than the bedside. But if our cell-based therapy development progress at BioRestorative, as well as that at several other companies, is any indication, it may not be long before the full clinical potential of the field is realized. I am energized by this unique opportunity to wor ...

- New journal section will focus on emerging and translation work in the field of regenerative medicine - "We are excited to expand the journal's focus on regenerative medicine and are thrilled to have found someone with Francisco's demonstrated research excellence, pioneering clinical experience, and ability to serve as a respected ambassador to become our newest Section Editor," said the Journal of Translational Medicine's Editor-in-Chief, Francesco Marincola, MD. Earlier in his career, in 2008, Mr. Silva ...

Core Insights - BioRestorative Therapies, Inc. has received a notice of allowance from the Japanese Patent Office for a patent related to its ThermoStem® platform, enhancing its intellectual property portfolio [6][7] - The company is actively expanding its ThermoStem® intellectual property estate to secure long-term market exclusivity for its BADSCs, which are aimed at treating obesity and metabolic disorders [2][11] - BioRestorative is engaged in substantive discussions with a commercial stage regenerative medicine company regarding a potential licensing agreement for its ThermoStem® metabolic intellectual property [12] Company Overview - BioRestorative develops therapeutic products using adult stem cells, focusing on two main clinical programs: treatment of disc/spine disease and metabolic disorders [3] - The company operates a commercial BioCosmeceutical platform, offering a cell-based secretome product designed to reduce fine lines and wrinkles, with plans to expand its product line [4] Metabolic Program - The ThermoStem® program utilizes brown adipose derived stem cells (BADSC) to generate brown adipose tissue (BAT), which is linked to increased caloric burning and reduced glucose and lipid levels [9] - Preclinical studies indicate that BADSCs can lead to significant reductions in weight, triglyceride, and blood glucose levels in animal models [11] Disc/Spine Program - The lead therapy candidate, BRTX-100, is formulated from a patient's own mesenchymal stem cells and is intended for non-surgical treatment of lumbosacral disc disorders [13] - A Phase 2 clinical trial for BRTX-100 has commenced, targeting chronic lower back pain due to degenerative disc disease [13]

MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Exchange Commission. Summary First Quar ...

- Potential license partner is a leading commercial stage regenerative medicine company – No assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise. The Company does not intend to make any further announcements with regard to the license unless and until an agreement is entered into. • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal ...

BADSCs with brown adipogenic potential would represent an exciting new modality for the treatment of obesity and related metabolic disorders. To explore this possibility, BioRestorative developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride and blood glucose levels compared to saline-only injected controls. No ...

Company Performance - Biorestorative Therapies reported revenues of $0.04 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 16.67% and up from $0.03 million year-over-year [2] - The company posted a quarterly loss of $0.53 per share, compared to the Zacks Consensus Estimate of a loss of $0.51, and a loss of $1.53 per share a year ago [8] - Biorestorative Therapies has surpassed consensus EPS estimates three times over the last four quarters [9] Stock Performance - Biorestorative Therapies shares have declined approximately 32.8% since the beginning of the year, while the S&P 500 has gained 12.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $0.03 million, and for the current fiscal year, it is -$1.96 on revenues of $0.12 million [5] Industry Context - The Medical - Biomedical and Genetics industry, to which Biorestorative Therapies belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [13] - The performance of Biorestorative Therapies may be influenced by the overall industry outlook, as top-ranked industries tend to outperform lower-ranked ones significantly [13]

For the Three Months Ended March 31, 2023 Series B Convertible Additional Preferred Stock Common Stock Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-----------|------------|-----------|-------|-------|--------------|----------------|---------------| | Return and cancellation of shares in lieu of payroll tax \nwithholding | - | - | (10,058) ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...